ArticleFrontiers in oncology2026
Treatment outcomes of gestational choriocarcinoma before and after EMA/CO introduction in Mongolia: a 15-year retrospective cohort study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the clinical characteristics, metastatic patterns, and treatment outcomes of gestational choriocarcinoma in Mongolia, with a particular focus on the impact of etoposide-methotrexate-actinomycin D/cyclophosphamide-vincristine (EMA/CO) chemotherapy implementation. Methods: A retrospective cohort study was conducted including 66 patients diagnosed with gestational choriocarcinoma between 2011 and 2025. Patients were stratified based on FIGO stage and metastatic status. Clinical features, antecedent pregnancy, and treatment outcomes were analyzed. Comparisons between pre-implementation (2011-2017) and post-implementation (2018-2025) cohorts were performed using independent t-test, chi-square test, or Fisher's exact test as appropriate. Results: Of the 66 patients, 42.4% (n = 28) had non-metastatic disease (FIGO stage I), while 57.6% (n = 38) presented with metastatic disease (FIGO stages II-IV). Vaginal bleeding was the most common presenting symptom (84.8%). The lungs were the most frequent site of metastasis. Following implementation of the EMA/CO chemotherapy regimen in 2018, higher complete remission rates and lower observed mortality were observed in the post-implementation cohort. Complete remission increased from 69.7% (23/33) to 97.0% (32/33) (p = 0.006), while disease-related mortality decreased from 30.3% (10/33) to 3.0% (1/33) (p = 0.006). Chemoresistance and relapse rates also decreased, although these differences were not statistically significant. Additional interventions, including surgery for residual disease and radiotherapy for brain or lung metastases, were applied when indicated. Despite overall improvements, metastatic disease remained a key determinant of prognosis. Conclusion: Patients treated after 2018 demonstrated higher complete remission rates and lower observed mortality compared with those treated before 2018. However, due to the retrospective design, absence of adjusted outcome analysis, and baseline differences between treatment-era cohorts, these findings should be interpreted cautiously. Early diagnosis, routine serum β-hCG surveillance, timely referral, and standardized management remain essential for optimizing outcomes in gestational choriocarcinoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.